Eli Lilly Prevails in Federal Circuit on Alimta Patent

August 2019

On August 9th, the United States Court of Appeals for the Federal Circuit ruled in favor of Williams & Connolly client Eli Lilly, affirming two trial court judgments holding generic competitors Dr. Reddy’s’ and Hospira’s proposed products would infringe Lilly’s patent protecting its blockbuster anti-cancer drug Alimta®.  This victory follows Lilly’s two previous wins before the Federal Circuit, where the court in a unanimous opinion affirmed two district court judgments concerning the Alimta® patent, and upheld three PTAB decisions denying inter partes review of the same patent. Williams & Connolly represented Lilly in both of those cases as well. 

Through these repeated victories, Williams & Connolly has helped secure Eli Lilly’s continued patent protection for Alimta®, a product with more than $1 billion in annual U.S. revenue.   

Eli Lilly is represented by Adam Perlman, Dov Grossman, David Krinsky, Galina Fomenkova, Luke McCloud, and Andrew Lemens.

back to top